MERTK/TYRO3 (Ab-753) Antibody

What are the TAM receptors and what is their significance in cellular biology?

TAM receptors constitute a family of receptor tyrosine kinases (RTKs) comprising TYRO3, AXL, and MERTK. These receptors play crucial roles in regulating multiple physiological processes including cell survival, migration, differentiation, and phagocytosis of apoptotic cells (efferocytosis). The TAM family also mediates important functions in platelet aggregation, cytoskeleton reorganization, and the regulation of inflammatory cytokine release .

TAM receptors transduce signals from the extracellular matrix into the cytoplasm by binding to several ligands including GAS6, LGALS3, TUB, and TULP1. Ligand binding at the cell surface induces autophosphorylation on the intracellular domain, providing docking sites for downstream signaling molecules . Dysregulation of TAM receptors has been implicated in various pathological conditions, particularly cancer development and progression.

What is the functional significance of phosphorylation sites in MERTK and TYRO3?

Phosphorylation at specific tyrosine residues is critical for activation and signaling capacity of TAM receptors:

MERTK phosphorylation sites:

• Tyr749: Mutation to phenylalanine reduces kinase activity to 39% of wild-type MERTK

• Tyr753: Mutation to phenylalanine reduces kinase activity to 10% of wild-type MERTK

• Tyr754: Mutation to phenylalanine reduces kinase activity to <6% of wild-type MERTK

These findings indicate that tri-phosphorylation of MERTK at Tyr749, Tyr753, and Tyr754 is essential for optimal kinase activity. Following activation, MERTK interacts with proteins such as GRB2 or PLCG2 to induce phosphorylation of downstream targets including MAPK1, MAPK2, FAK/PTK2, or RAC1, thus triggering various cellular responses .

TYRO3 phosphorylation occurs primarily at Tyr681 and Tyr685, with site-specific antibodies available for detection of these modifications .

How do MERTK and TYRO3 signaling pathways differ functionally?

Despite belonging to the same receptor family, MERTK and TYRO3 often exert opposing effects in cellular function. For example, in osteoblast biology:

This functional antagonism makes these receptors interesting targets for therapeutic intervention, as inhibition of one (e.g., MERTK) might effectively enhance the function of cellular processes normally suppressed by its activity .

What is the molecular basis for antibody recognition of phosphorylated MERTK (Tyr753)?

The Anti-MERTK phospho Y753 antibody is typically generated using a synthetic phospho-peptide corresponding to amino acid residues surrounding Tyr753 of human MERTK. This peptide is conjugated to a carrier protein like keyhole limpet hemocyanin (KLH) for immunization . The antibody specifically recognizes the ~160 kDa MERTK protein when phosphorylated at the Tyr753 residue.

For polyclonal antibodies, they are typically prepared from pooled rabbit serum by affinity purification via sequential chromatography on phospho- and non-phosphopeptide affinity columns to ensure phospho-specificity . This purification process eliminates antibodies that might cross-react with the non-phosphorylated form of the protein.

How should researchers select between single phospho-site (Y753) and multi-phospho-site (Y749/753/754) MERTK antibodies?

Selection should be based on the specific research question:

For studies examining the relationship between specific phosphorylation events and downstream signaling, single-site antibodies provide more precise mechanistic information. For general activation status assessment, multi-site antibodies may provide a more comprehensive picture .

What cross-reactivity considerations are important when using MERTK (Ab-753) in multi-species studies?

When designing studies involving multiple species, species cross-reactivity is a critical consideration. The available data indicates:

• Anti-MERTK (phospho Y753) antibodies typically react with human and mouse samples

• Some antibodies show broader reactivity including rat MERTK

• Species homology around the phosphorylation sites is high but not identical

Researchers should:

• Verify the specific species reactivity of their chosen antibody through manufacturer data and literature citations

• Validate antibody performance in their specific experimental system using appropriate positive and negative controls

• Consider species-specific amino acid sequence variations around the phosphorylation site that might affect antibody recognition

• For novel species applications, perform preliminary validation experiments comparing phosphorylated and non-phosphorylated samples

What are the optimal protocols for detecting MERTK (phospho Y753) in Western blot experiments?

For optimal detection of phosphorylated MERTK (Y753) in Western blot experiments, researchers should follow this methodological approach:

• Sample preparation:

  • Lyse cells in buffer containing phosphatase inhibitors (e.g., sodium orthovanadate, sodium fluoride, β-glycerophosphate)

  • For tissues, use rapid freezing followed by homogenization in cold lysis buffer with phosphatase inhibitors

  • Maintain samples at 4°C throughout processing

• Gel electrophoresis and transfer:

  • Use 7.5% or 4-12% gradient gels to properly resolve the 160 kDa MERTK protein

  • Transfer to PVDF membrane (preferred over nitrocellulose for phosphoproteins)

  • Transfer at low voltage (30V) overnight at 4°C for large proteins like MERTK

• Blocking and antibody incubation:

  • Block in 5% BSA (not milk, which contains phosphoproteins) in TBST

  • Incubate with primary antibody at 1:1000 dilution

  • Use gentle rocking at 4°C overnight

  • Wash extensively (5× 5 minutes) with TBST

• Detection and controls:

  • Use HRP-conjugated anti-rabbit secondary antibody followed by ECL detection

  • Include positive controls (cells treated with PROS1 or GAS6 to induce phosphorylation)

  • Include negative controls (phosphatase-treated lysates or MERTK-knockout samples)

For phosphorylation-specific detection, treatment of parallel samples with lambda phosphatase can confirm signal specificity.

How can researchers effectively distinguish between MERTK (Y753) and TYRO3 phosphorylation in co-expression systems?

Distinguishing between phosphorylated MERTK and TYRO3 in systems where both receptors are expressed requires careful experimental design:

• Molecular weight discrimination:

  • MERTK appears at approximately 160 kDa

  • TYRO3 typically migrates at a different molecular weight, allowing separation on gels

• Sequential immunoprecipitation approach:

  • First immunoprecipitate with receptor-specific (not phospho-specific) antibody

  • Then probe with phospho-specific antibody

  • This confirms which receptor is phosphorylated

• Use of receptor-specific knockdown/knockout:

  • Employ siRNA or CRISPR to specifically deplete one receptor

  • Compare phosphorylation signals in control vs. knockdown samples

• Selective stimulation:

  • Some ligands may preferentially activate one receptor over the other

  • Time-course experiments may reveal different activation kinetics

• Phospho-specific antibodies with validated specificity:

  • Use antibodies that have been tested against both phosphorylated receptors

  • Choose antibodies that recognize unique phosphopeptide sequences around the key tyrosine residues

Cross-validation with receptor-specific immunoprecipitation followed by phosphotyrosine blotting can provide additional confirmation.

What is the best way to quantify changes in MERTK (Y753) phosphorylation in response to inhibitor treatments?

Quantifying changes in MERTK (Y753) phosphorylation in inhibitor studies requires rigorous methodology:

• Normalization approach:

  • Always normalize phospho-MERTK signal to total MERTK expression

  • Use sequential probing of the same membrane (strip and reprobe) or parallel membranes

  • Calculate phospho-MERTK/total MERTK ratio for each sample

• Time-course considerations:

  • Include multiple time points (0, 5, 15, 30, 60 min) post-inhibitor treatment

  • This captures both rapid and sustained changes in phosphorylation

• Dose-response analysis:

  • Test multiple inhibitor concentrations to generate IC50 values for phosphorylation inhibition

  • Compare IC50 for phosphorylation with IC50 for downstream functional effects

• Data representation:

  • Present data as percentage of control (vehicle-treated) phosphorylation

  • Include statistical analysis across multiple independent experiments (n≥3)

Example quantification table format:

To verify specificity of inhibition, parallel assessment of other phosphorylation events (ERK, AKT) can help distinguish direct vs. indirect effects on MERTK phosphorylation.

How does MERTK (Y753) phosphorylation status correlate with cancer progression and therapeutic resistance?

MERTK phosphorylation at Y753 has significant implications for cancer biology:

• Correlation with disease progression:

  • Enhanced MERTK phosphorylation is associated with increased tumor growth, invasion, and metastasis across multiple cancer types

  • High levels of phosphorylated MERTK correlate with worse clinical outcomes in several malignancies

• Therapeutic resistance mechanisms:

  • MERTK phosphorylation activates pro-survival pathways including PI3K/AKT and MAPK signaling

  • This activation can bypass inhibition of other RTKs, conferring resistance to targeted therapies

  • Phosphorylated MERTK mediates resistance to both conventional chemotherapeutics and targeted therapies

• Downstream effectors:

  • Y753 phosphorylation is critical for recruitment of signaling adaptors and activation of downstream pathways

  • Loss of this phosphorylation site reduces MERTK kinase activity to approximately 10% of wild-type activity

  • Tumor cells with constitutive Y753 phosphorylation show enhanced survival under stress conditions

Monitoring MERTK Y753 phosphorylation in patient samples may provide biomarker information for predicting treatment response and disease progression.

What are the most effective experimental approaches to study MERTK inhibition in cancer models using phospho-specific antibodies?

To effectively study MERTK inhibition in cancer models using phospho-specific antibodies (including Ab-753), researchers should consider these approaches:

• In vitro cellular models:

  • Compare MERTK-dependent and independent cell lines based on phosphorylation status

  • Establish dose-response relationships between inhibitor concentration and Y753 phosphorylation

  • Correlate phosphorylation reduction with functional outcomes (proliferation, migration, survival)

• In vivo tumor models:

  • Use phospho-MERTK (Y753) antibodies for immunohistochemistry on tumor sections

  • Collect tumor samples at multiple timepoints post-inhibitor treatment

  • Compare phosphorylation in primary tumors versus metastatic lesions

• Combination therapy assessment:

  • Evaluate how MERTK inhibitors affect Y753 phosphorylation when combined with other therapies

  • Determine if phosphorylation status predicts synergistic or antagonistic drug interactions

• Resistance mechanisms:

  • Monitor Y753 phosphorylation in models of acquired resistance

  • Use phospho-specific antibodies to identify bypass mechanisms restoring downstream signaling

Representative experimental approach table:

For advanced studies, combining phospho-specific antibodies with proximity ligation assays can reveal interactions between phosphorylated MERTK and downstream effectors in situ.

How can researchers differentiate between oncogenic roles of MERTK versus TYRO3 phosphorylation in tumor models?

Distinguishing the oncogenic contributions of MERTK and TYRO3 phosphorylation requires sophisticated experimental approaches:

• Selective genetic manipulation:

  • Create cell lines with CRISPR-mediated knockout of either MERTK or TYRO3

  • Generate phospho-site mutants (Y753F in MERTK, Y681F in TYRO3)

  • Assess phenotypic differences in growth, survival, and metastatic potential

• Receptor-specific activation:

  • Utilize selective TAM receptor agonists where available

  • Employ receptor-specific antibodies that induce activation

  • Monitor downstream pathway activation patterns unique to each receptor

• Phosphorylation-specific antibody analysis:

  • Use validated antibodies that distinguish between phosphorylated forms

  • Perform simultaneous detection of both phospho-proteins in tumor samples

  • Correlate relative phosphorylation levels with tumor characteristics

• Bioinformatic approaches:

  • Analyze cancer genomic databases for differential expression/mutation of MERTK vs. TYRO3

  • Identify cancer subtypes with selective dependence on either receptor

  • Develop phosphorylation-specific gene signatures associated with each receptor

Research has shown differential roles in specific cancer types. For example, in bladder cancer, TYRO3 shows significantly higher expression in both non-muscle invasive and muscle-invasive subtypes compared to normal urothelium, with TYRO3 depletion substantially reducing tumor cell viability, while AXL and MERTK depletion had only minor effects . This contrasts with other cancers where MERTK may play the dominant role.

How do phosphorylation patterns of MERTK (Y753) and TYRO3 regulate bone homeostasis?

The TAM receptors MERTK and TYRO3 exert opposing effects on bone homeostasis through distinct phosphorylation-mediated signaling:

• Differential effects on bone mass:

  • Osteoblast-targeted deletion of MERTK promotes increased bone mass in both healthy mice and those with cancer-induced bone loss

  • Knockout of TYRO3 in osteoblasts produces the opposite effect (decreased bone mass)

• Phosphorylation-dependent pathways:

  • MERTK phosphorylation at Y753 is critical for interaction with its ligand PROS1

  • This interaction negatively regulates osteoblast differentiation via the VAV2-RHOA-ROCK axis

  • TYRO3 antagonizes this pathway, with its phosphorylation likely promoting osteoblast differentiation

• Cytoskeletal regulation via phosphorylation:

  • Phosphorylated MERTK increases cell contractility and motility, which inhibits osteoblast differentiation

  • TYRO3 phosphorylation has opposing effects on cytoskeletal organization

  • These cytoskeletal differences directly impact osteoblast function and bone formation

• Therapeutic implications:

  • Pharmacologic MERTK blockade by small molecule inhibitors (e.g., R992) increases osteoblast numbers and bone formation

  • Such inhibitors can counteract cancer-induced bone loss and reduce bone metastasis

  • Phosphorylation status of MERTK (Y753) could serve as a biomarker for treatment response

This research reveals that monitoring phosphorylation of these receptors provides insights into bone homeostasis regulation and potential therapeutic interventions for bone diseases.

What are the methodological challenges in studying MERTK (Y753) phosphorylation in bone tissue samples?

Analyzing MERTK phosphorylation in bone tissue presents unique methodological challenges:

• Tissue processing challenges:

  • Mineralized bone requires decalcification, which can affect phospho-epitope preservation

  • Standard EDTA-based decalcification may preserve phospho-epitopes better than acid-based methods

  • Rapid fixation is critical to prevent phosphatase activity during sample processing

• Cell-type heterogeneity:

  • Bone tissue contains multiple cell types (osteoblasts, osteoclasts, osteocytes)

  • Laser capture microdissection may be needed to isolate specific cell populations

  • Cell-specific markers must be used alongside phospho-MERTK detection

• Low abundance challenges:

  • MERTK is not highly expressed in all bone cells

  • Signal amplification methods may be required

  • Tyramide signal amplification or quantum dot-based detection can enhance sensitivity

• Validation approaches:

  • Use of phosphatase treatment controls on serial sections

  • Comparison with genetically modified models (MERTK Y753F knock-in)

  • Correlation of IHC results with Western blot from the same samples

• Quantification considerations:

  • Develop standardized scoring systems for phospho-MERTK intensity

  • Use digital pathology approaches for unbiased quantification

  • Include reference standards on each slide for inter-sample normalization

Researchers should consider these challenges when designing studies of MERTK phosphorylation in bone and develop appropriate validation strategies to ensure reliable results.

How can researchers address inconsistent detection of MERTK (Y753) phosphorylation across different experimental systems?

When facing inconsistent detection of MERTK Y753 phosphorylation, researchers should implement this systematic troubleshooting approach:

• Sample preparation factors:

  • Ensure rapid sample collection and processing to preserve phosphorylation

  • Verify phosphatase inhibitor cocktail effectiveness and freshness

  • Consider cell lysis conditions (detergent type and concentration can affect phospho-epitope exposure)

• Technical optimization:

  • Test multiple antibody dilutions (1:500 to 1:2000 range)

  • Evaluate different blocking agents (BSA vs. commercial blockers)

  • Optimize incubation times and temperatures for primary antibody

• Validation strategies:

  • Use positive controls (cells treated with known MERTK activators like GAS6)

  • Employ MERTK knockdown/knockout samples as negative controls

  • Consider phosphatase treatment of duplicate samples to confirm specificity

• System-specific considerations:

  • Cell culture: Serum starvation before stimulation may reduce background

  • Tissue samples: Optimize fixation time to preserve phospho-epitopes

  • Animal models: Consider strain-specific differences in MERTK expression/regulation

• Alternative approaches:

  • Try immunoprecipitation followed by phospho-tyrosine detection

  • Consider phospho-flow cytometry for cell suspensions

  • Use proximity ligation assays to detect phosphorylated MERTK in situ

When interpreting inconsistent results, context matters—baseline phosphorylation levels vary significantly across tissue types and experimental conditions.

What are the best practices for distinguishing specific from non-specific signals when using MERTK phospho-antibodies?

To distinguish specific from non-specific signals with MERTK phospho-antibodies:

• Essential controls:

  • Phosphatase-treated samples (lambda phosphatase)

  • MERTK knockdown/knockout samples

  • Y753F mutant MERTK expression (phospho-site mutant)

  • Peptide competition with phospho and non-phospho peptides

• Molecular weight verification:

  • MERTK should appear at approximately 160 kDa

  • Non-specific bands at other molecular weights can be documented

  • Secondary antibody-only control to identify non-specific binding

• Signal validation approaches:

  • Compare multiple antibodies targeting the same phospho-site

  • Correlate with total MERTK expression

  • Verify expected changes with known stimuli (GAS6, PROS1)

• Advanced validation:

  • Mass spectrometry verification of phosphorylation at Y753

  • Parallel analysis with phospho-receptor capture technology

  • Correlation with downstream pathway activation

• Documentation standards:

  • Present full blots with molecular weight markers

  • Include all controls in publication figures

  • Clearly state antibody source, catalog number, and lot number

  • Document optimization protocols used

How should researchers interpret changes in MERTK (Y753) phosphorylation in the context of conflicting downstream signaling data?

When faced with discrepancies between MERTK phosphorylation and expected downstream signaling, consider these analytical approaches:

• Time-course analysis:

  • Phosphorylation events occur in temporal cascades

  • MERTK Y753 phosphorylation may precede or follow other signaling events

  • Collect samples at multiple timepoints (minutes to hours) to capture dynamic relationships

• Pathway crosstalk consideration:

  • MERTK signaling interacts with other pathways (PI3K/AKT, MAPK)

  • These interactions may amplify or attenuate expected outcomes

  • Map the complete signaling network in your specific experimental system

• Threshold effects:

  • Certain levels of phosphorylation may be required for downstream signaling

  • Partial inhibition may not translate to proportional downstream effects

  • Quantify the relationship between percent phosphorylation and downstream activation

• Cell-specific factors:

  • Expression levels of adaptor proteins influence signaling outcomes

  • Presence of phosphatases can modulate duration of signaling

  • Cell type-specific feedback mechanisms may exist

• Technical verification:

  • Confirm antibody specificity for the phosphorylation site

  • Verify activity of positive and negative regulators of the pathway

  • Consider post-translational modifications beyond phosphorylation

When interpreting conflicting data, develop integrated models that incorporate pathway dynamics, thresholds, and cell-specific factors rather than expecting simple linear relationships between MERTK phosphorylation and downstream effects.

How might differential phosphorylation patterns between MERTK (Y753) and other sites (Y749, Y754) influence receptor function?

Understanding differential phosphorylation patterns provides deeper insights into MERTK regulation:

• Hierarchical phosphorylation model:

  • Sequential phosphorylation may occur, with certain sites functioning as "priming" events

  • Y753 phosphorylation reduces MERTK kinase activity to only 10% when mutated, suggesting it may be an early critical site

  • Temporal dynamics between phosphorylation at different sites could determine signaling outcomes

• Effector binding specificity:

  • Different phosphorylation patterns likely recruit distinct subsets of downstream effectors

  • Phosphorylation at Y753 versus other sites may preferentially activate certain pathways

  • This could explain context-dependent outcomes of MERTK activation

• Regulatory mechanisms:

  • Site-specific phosphatases may target particular phosphorylation sites

  • Conformational changes induced by single-site phosphorylation may influence accessibility of other sites

  • Ligand-specific effects might induce different phosphorylation patterns

• Therapeutic implications:

  • Site-selective inhibitors could potentially modulate specific MERTK functions while preserving others

  • Understanding the consequences of blocking phosphorylation at specific sites could lead to more precise therapeutic approaches

Future research should employ mass spectrometry-based approaches to map complete phosphorylation patterns and correlate them with functional outcomes across different cellular contexts.

What novel approaches can be developed for spatiotemporal monitoring of MERTK (Y753) phosphorylation in living systems?

Emerging technologies for dynamic monitoring of MERTK phosphorylation include:

• Genetically encoded biosensors:

  • FRET-based reporters incorporating MERTK phospho-binding domains

  • Split luciferase complementation systems triggered by phosphorylation

  • These allow real-time visualization of phosphorylation events in living cells

• Advanced microscopy techniques:

  • Super-resolution microscopy to localize phosphorylated MERTK within membrane microdomains

  • Correlative light and electron microscopy to connect phosphorylation with ultrastructural features

  • Light sheet microscopy for phosphorylation monitoring in 3D tissue models

• Phospho-proteomic approaches:

  • Targeted mass spectrometry with phospho-enrichment

  • Pulsed SILAC to determine phosphorylation turnover rates

  • Single-cell phospho-proteomics to address cellular heterogeneity

• In vivo monitoring strategies:

  • Phospho-specific antibody fragments conjugated to near-infrared fluorophores

  • Photoacoustic imaging with phospho-specific contrast agents

  • Radiolabeled tracers targeting phosphorylated MERTK for PET imaging

These approaches would provide unprecedented insights into the dynamics of MERTK phosphorylation in physiological and pathological contexts, potentially revealing new therapeutic opportunities and biological principles.

How does the interplay between MERTK (Y753) and TYRO3 phosphorylation affect therapeutic responses to TAM inhibitors?

Understanding the interplay between MERTK and TYRO3 phosphorylation is critical for optimizing therapeutic strategies:

• Compensatory mechanisms:

  • Inhibition of MERTK phosphorylation may lead to compensatory increases in TYRO3 phosphorylation

  • This compensation could undermine therapeutic efficacy in certain contexts

  • Dual monitoring of both receptors' phosphorylation status provides insight into resistance mechanisms

• Pathway redundancy and divergence:

  • MERTK and TYRO3 share some downstream effectors but also activate distinct pathways

  • The balance of phosphorylation between these receptors may determine which pathways predominate

  • This balance likely influences cellular responses to TAM inhibitors

• Tissue-specific considerations:

  • The relative importance of MERTK versus TYRO3 phosphorylation varies by tissue context

  • In bladder cancer, TYRO3-dependency appears more critical than MERTK or AXL

  • In bone biology, MERTK and TYRO3 have opposing effects on osteoblast function

• Implications for inhibitor design:

  • Pan-TAM inhibitors versus selective inhibitors have different clinical implications

  • Optimal phosphorylation site targeting depends on disease context

  • Some representative TAM inhibitors and their specificity profiles:

Future therapeutic strategies may involve selective modulation of phosphorylation at specific sites rather than complete inhibition of kinase activity, potentially offering improved efficacy and reduced off-target effects .